| P50 | author | Benjamin Djulbegovic | Q28050789 |
| | Margaret Piper | Q56526469 |
| | David L Veenstra | Q91864225 |
| | Stephen G. Pauker | Q97318958 |
| P2093 | author name string | Michael Marrone | |
| | Ned Calonge | |
| | Jennifer S Lin | |
| | Alfred O Berg | |
| | Sean R Tunis | |
| | James E Haddow | |
| | Roger Klein | |
| | Carolyn Sue Richards | |
| P2860 | cites work | The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration | Q21092360 |
| | Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q21562278 |
| | Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews | Q29547775 |
| | GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables | Q29547885 |
| | Current processes of the U.S. Preventive Services Task Force: refining evidence-based recommendation development | Q34638937 |
| | Validation of an index of the quality of review articles | Q34762592 |
| | Stakeholder perspectives on a risk-benefit framework for genetic testing | Q35546409 |
| | A formal risk-benefit framework for genomic tests: Facilitating the appropriate translation of genomics into clinical practice | Q35854145 |
| | Going from evidence to recommendations | Q36645665 |
| | Grading quality of evidence and strength of recommendations for diagnostic tests and strategies | Q36661809 |
| | Using existing systematic reviews in complex systematic reviews | Q37168112 |
| | The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group | Q37277889 |
| | A decade of public health genomics in the United States: centers for disease control and prevention 1997-2007. | Q37331241 |
| | Outcomes of interest in evidence-based evaluations of genetic tests | Q37684710 |
| | Use of genomic profiling to assess risk for cardiovascular disease and identify individualized prevention strategies--a targeted evidence-based review | Q37806581 |
| | Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer | Q37825721 |
| | Horizon scanning for new genomic tests | Q37828350 |
| | Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer. | Q37903703 |
| | Decision analysis for public health: principles and illustrations | Q40211944 |
| | Decision-analytic modeling to evaluate benefits and harms of medical tests: uses and limitations | Q43861328 |
| | Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. | Q52024329 |
| | The vexing problem of guidelines and conflict of interest: a potential solution. | Q53075951 |
| | Incorporating Patient Preferences in Evidence-Based Medicine—Reply | Q57695869 |
| | The Next Step in Guideline Development | Q57695884 |
| | Deploying whole genome sequencing in clinical practice and public health: meeting the challenge one bin at a time | Q57785176 |
| | Update on the methods of the U.S. Preventive Services Task Force: insufficient evidence | Q83288867 |
| | KRAS mutations and epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer | Q83503122 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | whole genome sequencing | Q2068526 |
| P304 | page(s) | 14-24 | |
| P577 | publication date | 2012-09-06 | |
| P1433 | published in | Genetics in Medicine | Q15765508 |
| P1476 | title | Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update | |
| P478 | volume | 15 | |